PainReform (PRFX) announced, through its pharmaceutical division, the closing of its previously announced investment in LayerBio. With this transaction, PainReform has acquired a majority equity interest in LayerBio and plans to initiate the next clinical trial of OcuRing-K, LayerBio’s lead investigational product for pain and inflammation control following cataract surgery.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRFX: